Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ex Vivo CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study

NCT07662369 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07662369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ex Vivo CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study
Lead sponsor
Ruijin Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haplo-identical hct, hematologic malignancy